GSK launches pneumococcal vaccine

Synflorix is a polysaccharide conjugate vaccine indicated for active immunisation against invasive disease and acute otitis media caused by Streptococcus pneumoniae.

Synflorix is licensed for use in infants and children aged from 6 weeks to 2 years.

It offers protection against the same 7 serotypes of S. pneumoniae as Prevenar, plus three additional strains (1, 5 and 7F). These 10 serotypes are collectively thought to be responsible for 56–90% of cases of invasive pneumococcal disease in children aged under 5 years in Europe.

View Synflorix drug record

Further information: GSK

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases